Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04044053 | Relative Bioavailability Study of a Modified-Release Formulation of PF-06865571 in Healthy Adult Participants | PHASE1 | COMPLETED | 12 | — | — | Aug 13, 2019 | Oct 31, 2019 | Nov 27, 2019 | 1 | Belgium |
All study participants
All study participants
All study participants
All study participants
| Arm | Type | Description |
|---|---|---|
| Relative Bioavailability | EXPERIMENTAL | Each participant will receive 400 mg IR, 400 mg MR, and 50 mg MR in the fed state, and 400 mg MR in the fasted state |
| Fasted State | EXPERIMENTAL | Comparison of 400 mg MR in fed and fasted states |
| Name | Type | Description |
|---|---|---|
| PF-06865571 400 mg Immediate Release (IR) in Fed State | DRUG | 400 mg IR dose in fed state |
| PF-06865571 50 mg Modified Release (MR) in Fed State | DRUG | 50 mg MR in fed state |
| PF-06865571 400 mg MR in Fed State | DRUG | 400 mg MR in fed state |
| PF-06865571 400 mg MR in Fasted State | DRUG | 400 mg MR in fasted state |
Inclusion Criteria: * Female participants of non-childbearing potential and male participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac tests. * Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total ...